Tumor necrosis factor antagonists in the treatment of multicentric reticulohistiocytosis: Current clinical evidence

Mol Med Rep. 2016 Jul;14(1):209-17. doi: 10.3892/mmr.2016.5253. Epub 2016 May 12.

Abstract

Multicentric reticulohistiocytosis (MRH) is a rare and debilitating systemic disorder characterized by cutaneous nodules and destructive polyarthritis. Due to its unknown etiology, the treatment of MRH varies with different rates of success, which causes treatment options to be rather independent and empirical. In the present study, a case of a 48‑year‑old woman with a 12‑month history of polyarthralgia and skin nodules was reported. Biopsy samples, which were obtained from her skin eruption exhibited dermal infiltration with histiocytes and multinucleated giant cells. Immunohistochemical staining indicated positivity for CD68. The patient was diagnosed with MRH and treated with a combination therapy of infliximab, prednisolone and methotrexate. Her symptoms improved markedly within 2 weeks. Following the results of this case study, a systematic review of 17 cases of MRH treated with tumor necrosis factor (TNF) antagonists was performed, and the efficacy of anti‑TNF treatment in MRH was analyzed.

Publication types

  • Case Reports
  • Review
  • Systematic Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Arthritis / diagnosis
  • Arthritis / drug therapy
  • Arthritis / etiology
  • Arthritis / metabolism
  • Biomarkers
  • Female
  • Histiocytosis / diagnosis
  • Histiocytosis / drug therapy*
  • Histiocytosis / etiology
  • Histiocytosis / metabolism*
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Skin Diseases / diagnosis
  • Skin Diseases / drug therapy
  • Skin Diseases / etiology
  • Skin Diseases / metabolism
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors*

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • Tumor Necrosis Factor Inhibitors